# Clonal hematopoiesis in AML long‐term survivors: Risk factors and clinical consequences

## TL;DR

This study finds that clonal hematopoiesis is common in AML survivors and may increase the risk of diabetes and other cancers.

## Contribution

The study reveals the prevalence and clinical consequences of clonal hematopoiesis in AML long-term survivors.

## Key findings

- CH variants were detected in 61.9% of AML long-term survivors.
- Chemotherapy-treated survivors had higher CH prevalence compared to those who received alloSCT.
- CH variants ≥10% VAF were linked to diabetes in alloSCT recipients and secondary neoplasms in chemotherapy-treated survivors.

## Abstract

Clonal hematopoiesis (CH) is common in the general population and associated with various health risks, but its prevalence and clinical implications in acute myeloid leukemia (AML) long‐term survivors (LTS; ≥5‐year survival) are unknown. We analyzed CH in 373 AML‐LTS with a median 11.6‐year follow‐up from diagnosis using a sensitive targeted sequencing assay based on single‐molecule molecular inversion probes. CH variants were detected in 61.9% of survivors, with 26% having small‐clone CH (SC‐CH, variant allele frequency (VAF) < 2%) and 35.9% CH of indeterminate potential (≥2% VAF). CH was more prevalent in survivors treated with chemotherapy only (75.7%) compared to those who received allogeneic stem cell transplantation (alloSCT, 54.0%) and to age group‐matched healthy controls. In chemotherapy‐treated survivors, CH prevalence increased with age, whereas in alloSCT recipients, it most closely associated with hematopoietic age (i.e., the sum of donor age and time since transplantation). The variant spectrum also differed by treatment, with TP53 and PPM1D variants being more common in the chemotherapy group. CH variants ≥10% VAF associated with increased risks of diabetes in alloSCT recipients and secondary neoplasms in chemotherapy‐treated survivors. This study provides insights into the high prevalence and potential clinical relevance of CH in AML‐LTS.